Bachem Holding AG

Research Bachem Holding AG (BANB) on Bullrun: market cap CHF 5.80B, P/E 39.0, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CHF 5.80B; P/E is 39.0; dividend yield is 1.2%.

Peer valuation comparison

Latest P/E is 39.02x versus a Healthcare sector median of 24.46x (59.5% above).

Latest dividend yield is 1.17% versus a Healthcare sector median of 2.11% (44.5% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CHF 695.07MCHF 148.79M-CHF 57.82M28.7%1.98CHF 30.99Mn/aCHF 1.46B
FY2024CHF 605.26MCHF 120.25M-CHF 138.30M30.2%1.6CHF 95.20MCHF 290.00KCHF 1.39B
FY2023CHF 577.32MCHF 111.86M-CHF 18.54M30.7%1.5CHF 157.73MCHF 401.00KCHF 1.32B
FY2022CHF 531.74MCHF 100.68M-CHF 49.70M32.2%1.37CHF 31.45MCHF 352.00KCHF 1.17B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CHF 5.80B39.01.2%0.9

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.9 CHF, yield 1.2%.

YearDividends/share
FY20250.85 CHF
FY20240.8 CHF
FY20230.75 CHF
FY20220.7 CHF
FY20210.65 CHF

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Bachem Holding AG's market cap?

Bachem Holding AG's market capitalization is CHF 5.80B.

What is Bachem Holding AG's P/E ratio?

Bachem Holding AG's price-to-earnings (P/E) ratio is 39.0.

Does Bachem Holding AG pay a dividend?

Bachem Holding AG has a dividend yield of 1.2%.

What does Bachem Holding AG do?

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.